Delayed Adjuvant Herceptin® Treatment in Patients With HER-2 Positive Breast Cancer
Status:
Terminated
Trial end date:
2007-10-01
Target enrollment:
Participant gender:
Summary
The purpose of the study is to determine what factors affect a patient's decision to accept
delayed Herceptin® treatment after completing their surgery and/or chemotherapy and/or
radiation therapy.
Women with invasive breast cancer that have a HER-2 positive (FISH +) determination in 2004
or thereafter and who have completed surgery and primary treatment earlier will be
potentially eligible.
Patients will be asked to complete a questionnaire about their breast cancer and reasons why
they may or may not accept Herceptin® treatment. Patients will be given the option to (1)
receive Herceptin® for 52 weeks and have annual doctor visits for 5 years or (2) not to
receive Herceptin® but agree to annual doctor visits for 5 years.